I n the race to find a drug to defeat Alzheimer’s — the memory-robbing disease affecting millions of older Americans — leaders of a small South San Francisco company believe they’ve nailed an overlooked culprit: a brain-infecting bacteria. Now Cortexyme Inc., which has received funding from Big Pharma and deep-pocketed foundations alike, is taking its lead drug into its first human studies in attempt to prove that an infection is the source of Alzheimer’s. The undisclosed bacteria that Cortexyme’s drug is targeting has been found in the brain tissue and cerebral spinal fluid of Alzheimer’s patients.
- Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
- Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants with Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
- Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
- Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
- Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021